SUMMARY
Global Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY FINDINGS
Essential resource for top-line data and analysis covering the Global generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
REASONS TO BUY
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
The global generics market is expected to generate total revenues of $318bn in 2016, representing a compound annual growth rate (CAGR) of 11.1% between 2012 and 2016.
Market consumption volume is forecast to increase with a CAGR of 1.4% between 2012 and 2016, to reach a total of 78.6% of total pharma volume in 2016.
The onset of the global economic crisis has led to several countries strengthening their generic policies. These policies have contributed to the strong growth experienced in this market in recent years.
Global Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY FINDINGS
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in the global
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the global generics market
- Leading company profiles reveal details of key generics market players' global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Global generics market with five year forecasts by both value and volume
Essential resource for top-line data and analysis covering the Global generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
REASONS TO BUY
- What was the size of the Global generics market by value in 2016?
- What will be the size of the Global generics market in 2021?
- What factors are affecting the strength of competition in the Global generics market?
- How has the market performed over the last five years?
- How large is the global's generics market in relation to its regional counterparts?
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
The global generics market is expected to generate total revenues of $318bn in 2016, representing a compound annual growth rate (CAGR) of 11.1% between 2012 and 2016.
Market consumption volume is forecast to increase with a CAGR of 1.4% between 2012 and 2016, to reach a total of 78.6% of total pharma volume in 2016.
The onset of the global economic crisis has led to several countries strengthening their generic policies. These policies have contributed to the strong growth experienced in this market in recent years.
Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Allergan plc
Mylan Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Allergan plc
Mylan Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
LIST OF TABLES
Table 1: Global generics market value: $ billion, 2012-16(e)
Table 2: Global generics market volume: % of total pharma volume, 2012-16(e)
Table 3: Global generics market geography segmentation: $ billion, 2016(e)
Table 4: Global generics market value forecast: $ billion, 2016-21
Table 5: Global generics market volume forecast: % of total pharma volume, 2016-21
Table 6: Allergan plc: key facts
Table 7: Allergan plc: key financials ($)
Table 8: Allergan plc: key financial ratios
Table 9: Mylan Inc.: key facts
Table 10: Mylan Inc.: key financials ($)
Table 11: Mylan Inc.: key financial ratios
Table 12: Sandoz International GmbH: key facts
Table 13: Teva Pharmaceutical Industries Limited: key facts
Table 14: Teva Pharmaceutical Industries Limited: key financials ($)
Table 15: Teva Pharmaceutical Industries Limited: key financial ratios
Table 1: Global generics market value: $ billion, 2012-16(e)
Table 2: Global generics market volume: % of total pharma volume, 2012-16(e)
Table 3: Global generics market geography segmentation: $ billion, 2016(e)
Table 4: Global generics market value forecast: $ billion, 2016-21
Table 5: Global generics market volume forecast: % of total pharma volume, 2016-21
Table 6: Allergan plc: key facts
Table 7: Allergan plc: key financials ($)
Table 8: Allergan plc: key financial ratios
Table 9: Mylan Inc.: key facts
Table 10: Mylan Inc.: key financials ($)
Table 11: Mylan Inc.: key financial ratios
Table 12: Sandoz International GmbH: key facts
Table 13: Teva Pharmaceutical Industries Limited: key facts
Table 14: Teva Pharmaceutical Industries Limited: key financials ($)
Table 15: Teva Pharmaceutical Industries Limited: key financial ratios
LIST OF FIGURES
Figure 1: Global generics market value: $ billion, 2012-16(e)
Figure 2: Global generics market volume: % of total pharma volume, 2012-16(e)
Figure 3: Global generics market geography segmentation: % share, by value, 2016(e)
Figure 4: Global generics market value forecast: $ billion, 2016-21
Figure 5: Global generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the global generics market, 2016
Figure 7: Drivers of buyer power in the global generics market, 2016
Figure 8: Drivers of supplier power in the global generics market, 2016
Figure 9: Factors influencing the likelihood of new entrants in the global generics market, 2016
Figure 10: Factors influencing the threat of substitutes in the global generics market, 2016
Figure 11: Drivers of degree of rivalry in the global generics market, 2016
Figure 12: Allergan plc: revenues and profitability
Figure 13: Allergan plc: assets and liabilities
Figure 14: Mylan Inc.: revenues and profitability
Figure 15: Mylan Inc.: assets and liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues and profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets and liabilities
COMPANIES MENTIONED
Allergan plc
Mylan Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Skip to top
Figure 1: Global generics market value: $ billion, 2012-16(e)
Figure 2: Global generics market volume: % of total pharma volume, 2012-16(e)
Figure 3: Global generics market geography segmentation: % share, by value, 2016(e)
Figure 4: Global generics market value forecast: $ billion, 2016-21
Figure 5: Global generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the global generics market, 2016
Figure 7: Drivers of buyer power in the global generics market, 2016
Figure 8: Drivers of supplier power in the global generics market, 2016
Figure 9: Factors influencing the likelihood of new entrants in the global generics market, 2016
Figure 10: Factors influencing the threat of substitutes in the global generics market, 2016
Figure 11: Drivers of degree of rivalry in the global generics market, 2016
Figure 12: Allergan plc: revenues and profitability
Figure 13: Allergan plc: assets and liabilities
Figure 14: Mylan Inc.: revenues and profitability
Figure 15: Mylan Inc.: assets and liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues and profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets and liabilities
COMPANIES MENTIONED
Allergan plc
Mylan Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Healthcare in a Recession (OTC, Generics, Out of Pocket Spending, Healthcare Legislation, Retail Clinics, Outsourcing and Other Topics)
US$ 1,995.00
Mar, 2009 · 185 pages
